Alembic Pharmaceuticals Ltd (‘ALPM’) reported a weaker than expected Q1FY22 performance on the back of headwinds in key products (Sartans..
All is well
* We maintain Buy on DRL but lower our TP to Rs5,755 from Rs5,935, as we trim FY22/23/24E EPS (excl. gRevlimid) by 6%/4%/2% to reflect the Q1 miss. In our ..
Dr. Reddys Laboratories is currently trading at Rs. 4706.35, down by 138.00 points or 2.85% from its previous closing of Rs. 4844.35 on the BSE.
The scrip opened at Rs..
Dr Reddys’ management exuded optimism on regaining earlier (~25%) margin trajectory; it emphasized that Q1 represented a timing mismatch with price eros..
Torrent seems to have dodged any further erosion in US business particularly when other peers like ALPM and DRRD have been impacted; indeed, US sales have bee..
Sun Pharma Advanced Research Company is currently trading at Rs. 243.40, down by 17.60 points or 6.74% from its previous closing of Rs. 261.00 on the BSE.
The scrip op..
Alembic has withdrawn its FY22 guidance of Rs50 EPS which was reiterated in Q4 FY21. More than the sharp fall in US, what has led to the withdrawal is the unc..
India is among the top 10 countries in pharma and healthcare sector with exponential growth recorded in the last five years, according to a report by Sagacious IP, ..
MTF Stock Pick Buy GlaxoSmithKline Pharmaceuticals Ltd For Target Rs. 1850 - HDFC Securities
* The attached da..
Regulatory woes intensify at Roorkee
* The USFDA recently issued an Import Alert at Jubilant Pharmova (JP)’s Roorkee facility, escalating the regulatory concerns..
A 30% revenue growth quarter should uniformly boost confidence and bolsters our belief of a sustainable revenue growth phase. While we would have ideally like..
Focus on improving ESG initiatives.
We hosted Dr. Reddy’s Laboratories’ (DRL) in our ESG conference. The company was represented by Mr Parag Agarwal (CFO),..
Rupee falls 10 paise to 73.94 against US dollar in early trade
Rupee strengthens against US dollar on Tuesday
Rate decision, US stimulus likely constraints to rupee's further appreciation
Rupee slips on RBI's dovish stance, 'loose' policy
Currency Squeeze: Rupee expected to weaken further
View on Coforge Q1FY22 Result Update First cut by Mr. Piyush Pandey, YES Securities
Benchmarks likely to make positive start of F&O series expiry session
Chinese stocks in tentative bounce, Fed in no hurry to taper
Market is expected to open on flattish note and likely to witness sideways move during the day - Nirmal Bang
© Copyright 2017 - investmentguruindia | All Rights Reserved. | Crafted By - Digi Interface